Risperidone: Effects of formulations on oral bioavailability

Pharmacotherapy

Volumn 17, Issue 3, 1997, Pages 599-605

  Gutierrez, Rolando ^a   Lee, Peter I D ^a   Huang, May Lynn ^b   Woestenborghs, Robert ^b  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; PALIPERIDONE; RISPERIDONE; UNCLASSIFIED DRUG;

ADULT; ANGINA PECTORIS; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG HALF LIFE; DRUG SOLUTION; HUMAN; HUMAN EXPERIMENT; MALE; NEUROTOXICITY; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SOMNOLENCE; TABLET;

ADULT; ANTIPSYCHOTIC AGENTS; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; HUMANS; ISOXAZOLES; MALE; PYRIMIDINES; RISPERIDONE; SOLUTIONS; TABLETS; THERAPEUTIC EQUIVALENCY;

EID: 0031009486     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Leysen JE, Gommeren W, Eens A, et al. Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 1988;247:661-70.
2. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-35.
3. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13: 25-40.
4. Borison RL, Pathiraja AP, Diamond B, Meibach RC. Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacol Bull 1992;28:213-18.
5. Claus A, Bollen J, De Cuyper H, et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand 1992;85:295-305.
6. Grant S, Fitton A. Risperidone: a review of its pharmacology and therapeutic potential in the treatment of schizophrenia. Drugs 1994;48:253-73.
7. Heykants J, Huang ML, Mannens G, et al. The pharmacokinetics of risperidone in humans: a summary. J Clin Psychiatry 1994;55:S13-17.
8. Mannes G, Huang ML, Meuldermans W, et al. Absorption, metabolism, and excretion of risperidone in humans. Drug Metab Dispos 1993;21:1134-41.
9. Huang ML, Van Peer A, Woestenborghs R, et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 1993;54:257-68.
10. Ereshefsky L, Lacombe S. Pharmacological profile of risperidone. Can J Psychiatry 1993;38(suppl 3):S80-8.
11. Megens AAHP, Awouters FHL. In vivo pharmacological profile of 9-hydroxyrisperidone, the major metabolite of the novel antipsychotic risperidone. Drug Dev Res 1994;33: 399-412.
12. Schuirmann DJ. A comparison of two one-side test procedures and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987;15: 657-80.
13. Jonkman JHG, Zylicz Z. A bioequivalence study comparing 1 mg and 2 mg risperidone tablets with a 2 mg research tablet and an oral solution in healthy male volunteers. Clinical research report RIS-HOL-9004. Beerse, Belgium: Janssen Research Foundation, 1992.
14. Borison RL, Diamond B, Pathiraja A, Meibach RC. Pharmacokinetics of risperidone in chronic schizophrenic patients. Psychopharmacol Bull 1994;30:193-7.
15. Mesotten F, Suy E, Pietquin M, et al. Therapeutic effect and safety of increasing doses of risperidone in psychotic patients. Psychopharmacology 1989;99:445-9.
16. Nyberg S, Dahl ML, Halldin C. A PET study of D2 and 5-HT2 receptor occupancy in poor metabolizers of debrisoquine and risperidone. Psychopharmacology 1995;119:345-8.